The European Commission granted Orphan Drug Designation to Benitec Biopharma Ltd.'s (Nasdaq: BNTC) oculopharyngeal muscular dystrophy treatment BB-301 sending the stock price soaring $1.15 to close at $3.00.
Orphan Drug Designation granted to Benitec BiopharmaJanuary 17, 2017 at 16:34 PM EST
The European Commission granted Orphan Drug Designation to Benitec Biopharma Ltd.'s (Nasdaq: BNTC) oculopharyngeal muscular dystrophy treatment BB-301 sending the stock price soaring $1.15 to close at $3.00.
Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|